

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-25. (Canceled)

26. (Currently Amended) A method of specifically inhibiting fusion of an HIV-1 envelope glycoprotein⁺ cell with a CD4⁺ cell that fuses with such HIV-1 envelope glycoprotein⁺ cell, which comprises contacting the CD4⁺ cell with an anti-PM1 monoclonal antibody that (1) inhibits HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{JR-FL} to a PM1 cell, but (2) does not inhibit HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{LAI} to a HeLa-CD4⁺ cell, so as to thereby inhibit fusion of the HIV-1 envelope glycoprotein⁺ cell with the CD4⁺ cell.

27. (Canceled) ~~The method of claim 26, wherein the antibody is a monoclonal antibody.~~

28. (Currently Amended) The method of claim 26 27, wherein the anti-PM1 monoclonal antibody is a chimeric antibody.

29. (Currently Amended) The method of claim 26 27, wherein the anti-PM1 monoclonal antibody is a synthetic antibody.

30. (Currently Amended) The method of claim 26, wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.

31. (Currently Amended) A method of inhibiting infection of a CD4⁺ cell by HIV-1, which comprises contacting the CD4⁺ cell with an anti-PM1 monoclonal antibody that (1) inhibits HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{JR-FL} to a PM1 cell, but (2) does not inhibit HIV-1 envelope glycoprotein mediated membrane fusion of HeLa-env_{LAI} to a HeLa-CD4⁺ cell, so as to thereby inhibit infection of the CD4⁺ cell by HIV-1.

Applicants: Graham P. Allaway et al.
Serial No.: 09/904,356
Filed: July 12, 2001
Page 3

32. (Canceled) ~~The method of claim 31, wherein the antibody is a monoclonal antibody.~~

33. (Currently Amended) The method of claim 31 32, wherein the anti-PM1 monoclonal antibody is a chimeric antibody.

34. (Currently Amended) The method of claim 31 32, wherein the anti-PM1 monoclonal antibody is a synthetic antibody.

35. (Currently Amended) The method of claim 31, wherein the anti-PM1 monoclonal antibody is an antigen binding fragment of an antibody.